Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome.

Abstract

Rats were treated as neonates with 6-hydroxydopamine (6-OHDA) 100 mg free base in 10 microl intracisternally. Upon maturation, animals were injected with L-dopa and placed in photocell cages for monitoring of locomotion, stereotypies, and self-mutilation. Pretreatment with either risperidone or SCH-23390 significantly reduced locomotion and stereotypies. SCH-23390 eliminated L-dopa induced self-mutilation in all subjects, while risperidone eliminated self-mutilation in all but one subject.

• Authors: S M Allen, J N Freeman, W M Davis
• Journal: Pharmacology, biochemistry, and behavior (Pharmacol Biochem Behav) Vol. 59 Issue 2 Pg. 327-30 (Feb 1998) ISSN: 0091-3057 [Print] United States
• PMID: 9476977 (Publication Type: Journal Article)

Chemical References

• Benzazepines
• Dopamine Agents
• Dopamine Antagonists
• Sympatholytics
• Levodopa
• Oxidopamine
• Risperidone

Topics

• Animals
• Animals, Newborn
• Behavior, Animal (drug effects)
• Benzazepines (pharmacology)
• Disease Models, Animal
• Dopamine Agents (pharmacology)
• Dopamine Antagonists (therapeutic use)
• Dose-Response Relationship, Drug
• Female
• Lesch-Nyhan Syndrome (chemically induced, drug therapy, psychology)
• Levodopa (pharmacology)
• Male
• Motor Activity (drug effects)
• Oxidopamine (toxicity)
• Rats
• Rats, Sprague-Dawley
• Risperidone (therapeutic use)
• Self Mutilation (drug therapy, psychology)
• Sympatholytics (toxicity)